Publikasjoner

SESAM har hittil i 2023 hatt 53 publikasjoner i ulike tidsskrifter, der 14 er nivå 2 publikasjoner. ​

1. Aakre JA, Holteng LB, Testad I ​

   Healthy community-dwelling older adults’experience with a nutritional educational intervention: A feasibility study  Gerontechnology 
   

2. Aarsland D, Khalifa K, Bergland AK, Soennesyn H, Oppedal K, Holteng LBA, Oesterhus R, Nakling A, Jarholm JA, Lucia Cd, Fladby T, Broker H, Dalen I, Ballard C. 
   
   A randomised placebo-controlled study of purified anthocyanins on cognition in individuals at increased risk for dementia​. ​Am J Geriatr Psychiatry
   
   
3. Abdelnour C, Gonzalez MC, Gibson LL, Poston KL, Ballard CG, Cummings JL, Aarsland D. 
   Dementia with Lewy Bodies Drug Therapies in Clinical Trials: Systematic Review up to 2022 - PubMed (nih.gov) Neurol Ther. 
   
   
4. ​Altomare D, Stampacchia S, Ribaldi F, Tomczyk S, Chevalier C, Poulain G, Asadi S, Bancila B, Marizzoni M, Martins M, Lathuiliere A, Scheffler M, Ashton NJ, Zetterberg H, Blennow K, Kern I, Frias M, Garibotto V, Frisoni GB. 
   Plasma biomarkers for Alzheimer's disease: a field-test in a memory clinic.   
   J Neurol Neurosurg Psychiatry.
   
   
5. Bellaver B, Povala G, Ferreira PCL, Ferrari-Souza JP, Leffa DT, Lussier FZ, Benedet AL, Ashton NJ, Triana-Baltzer G, Kolb HC, Tissot C, Therriault J, Servaes S, Stevenson J, Rahmouni N, Lopez OL, Tudorascu DL, Villemagne VL, Ikonomovic MD, Gauthier S, Zimmer ER, Zetterberg H, Blennow K, Aizenstein HJ, Klunk WE, Snitz BE, Maki P, Thurston RC, Cohen AD, Ganguli M, Karikari TK, Rosa-Neto P, Pascoal TA.
   Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's disease  Nat Med. 
   ​
   

6. Bilgel M, An Y, Walker KA, Moghekar AR, Ashton NJ, Kac PR, Karikari TK, Blennow K, Zetterberg H, Jedynak BM, Thambisetty M, Ferrucci L, Resnick SM.
   Longitudinal changes in Alzheimer's-related plasma biomarkers and brain amyloid - PubMed Alzheimers Dement. 
   

7. Brem AK, Kuruppu S, de Boer C, Muurling M, Diaz-Ponce A, Gove D, Curcic J, Pilotto A, Ng WF, Cummins N, Malzbender K, Nies VJM, Erdemli G, Graeber J, Narayan VA, Rochester L, Maetzler W, Aarsland D.
   Digital endpoints in clinical trials of Alzheimer's disease and other neurodegenerative diseases: challenges and opportunities Front Neurol. 
   

8. Castellanos-Perilla N, Garcia-Cifuentes E, Pineda-Ortega J, Lema S, Gelvis G, Cano-Gutierrez CA, Mejia-Vergara AJ. 
   Self-reported glaucoma prevalence and related factors, contribution to reported visual impairment, and functional burden in a cross-sectional study in Colombia. Int Ophthalmol. 

9. Chai YL, Lee JH, Chong JR, Ballard C, Francis PT, Kennedy BK, Arumugam TV, Chen CP, Aarsland D, Lai MKP.
   Inflammatory panel cytokines are elevated in the neocortex of late-stage Alzheimer's disease but not Lewy body dementias J Neuroinflammation. 

10. Chong JR, Chai YL, Xing H, Herr DR, Wenk MR, Francis PT, Ballard C, Aarsland D, Silver DL, Chen CP, Cazenave-Gassiot A, Lai MKP.
    Decreased DHA-containing phospholipids in the neocortex of dementia with Lewy bodies are associated with soluble Aβ42 , phosphorylated α-synuclein, and synaptopathology Brain Pathol. 

11. Creese B, Arathimos R, Aarsland D, Ballard C, Brooker H, Hampshire A, Corbett A, Ismail Z.
    ​Late-life onset psychotic symptoms and incident cognitive impairment in people without dementia: Modification by genetic risk for Alzheimer's disease Alzheimers Dement (N Y). 
    

12. Csajbók Z, Aarsland D, Cermakova P. 
    

    Between-person and within-person effects in the temporal relationship between depressive symptoms and cognitive function. J Affect Disord. ​
    ​
13. Da Silva MV, Melendez-Torres GJ, Ismail Z, Testad I, Ballard C, Creese B 
    Adata-driven examination of apathy and depressive symptoms in dementia withindependent replication.​​​  Alzheimers Dement (Amst).
    
    
14. Dittrich A, Ashton NJ, Zetterberg H, Blennow K, Zettergren A, Simrén J, Skillbäck T, Shams S, Machado A, Westman E, Schöll M, Skoog I, Kern S.
    Association of Chronic Kidney Disease With Plasma NfL and Other Biomarkers of Neurodegeneration: The H70 Birth Cohort Study in Gothenburg Neurology. 
    
    
15. Donaghy PC, Carrarini C, Ferreira D, Habich A, Aarsland D, Babiloni C, Bayram E, Kane JP, Lewis SJ, Pilotto A, Thomas AJ, Bonanni L; Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment Lewy Body Dementias Prodromal Working Group. 
    ​​Research diagnostic criteria for mild cognitive impairment with Lewy bodies: A systematic review and meta-analysis Alzheimers Dement. 
    
    
16. Erickson P, Simrén J, Brum WS, Ennis GE, Kollmorgen G, Suridjan I, Langhough R, Jonaitis EM, Van Hulle CA, Betthauser TJ, Carlsson CM, Asthana S, Ashton NJ, Johnson SC, Shaw LM, Blennow K, Andreasson U, Bendlin BB, Zetterberg H; ADNI Cohort.
    ​Prevalence and Clinical Implications of a β-Amyloid-Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease  JAMA Neurol. 
    
    
17. Ferrari-Souza JP, Lussier FZ, Leffa DT, Therriault J, Tissot C, Bellaver B, Ferreira PCL, Malpetti M, Wang YT, Povala G, Benedet AL, Ashton NJ, Chamoun M, Servaes S, Bezgin G, Kang MS, Stevenson J, Rahmouni N, Pallen V, Poltronetti NM, O'Brien JT, Rowe JB, Cohen AD, Lopez OL, Tudorascu DL, Karikari TK, Klunk WE, Villemagne VL, Soucy JP, Gauthier S, Souza DO, Zetterberg H, Blennow K, Zimmer ER, Rosa-Neto P, Pascoal TA. 
    

    APOE ε4 associates with microglial activation independently of Aβ plaques and tau tangles. Sci Adv. 
    
    
18. Festari C, Massa F, Cotta Ramusino M, Gandolfo F, Nicolosi V, Orini S, Aarsland D, Agosta F, Babiloni C, Boada M, Borroni B, Cappa S, Dubois B, Frederiksen KS, Froelich L, Garibotto V, Georges J, Haliassos A, Hansson O, Jessen F, Kamondi A, Kessels RPC, Morbelli S, O'Brien JT, Otto M, Perret-Liaudet A, Pizzini FB, Ritchie CW, Scheltens P, Vandenbulcke M, Vanninen R, Verhey F, Vernooij MW, Yousry T, Van Der Flier WM, Nobili F, Frisoni GB.
    European consensus for the diagnosis of MCI and mild dementia: Preparatory phase  Alzheimers Dement. Front Med (Lausanne). 
    ​
    

19. Fusdahl P, Cummings J, Ballard C, Borda MG, Aarsland D. 
    The impact of low dementia research funding on brain health for decision makers: A reflection on current health statistics. J Neurol Sci.  

20. García-Chanes RE, Avila-Funes JA, Borda MG, Pérez-Zepeda MU, Gutiérrez-Robledo LM.
    ​​Higher frailty levels are associated with lower cognitive test scores in a multi-country study: evidence from the study on global ageing and adult health 
    

21. Gibson LL, Pollak TA, Hart M, Heslegrave A, Hye A, Church AJ, Lakdawala N, Nicholson TR, Batzu L, Rota S, Trivedi D, Zetterberg H, Chaudhuri KR, Aarsland D. 
    NMDA Receptor Antibodies and Neuropsychiatric Symptoms in Parkinson's Disease.  J Neuropsychiatry Clin Neurosci.

22. Gibson LL, Abdelnour C, Chong J, Ballard C, Aarsland D.
    Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers Curr Opin Neurol. 
    

23. Glebov OO, Williamson D, Owen DM, Hortobágyi T, Troakes C, Aarsland D. 
    Structural synaptic signatures of Alzheimer's disease and dementia with Lewy bodies in the male brain. Neuropathol Appl Neurobiol.  
24. Glebov OO, Mueller C, Stewart R, Aarsland D, Perera G.
    Antidepressant drug prescription and incidence of COVID-19 in mental health outpatients: a retrospective cohort study BMC Med. ​
    ​
    
25. Gonzalez-Ortiz F, Dulewicz M, Ashton NJ, Kac PR, Zetterberg H, Andersson E, Yakoub Y, Hanrieder J, Turton M, Harrison P, Nellgård B, Karikari TK, Blennow K.
    Association of Serum Brain-Derived Tau With Clinical Outcome and Longitudinal Change in Patients With Severe Traumatic Brain Injury  JAMA Netw Open
    
    
26. Gonzalez MC, Tovar-Rios DA, Alves G, Dalen I, Williams-Gray CH, Camacho M, Forsgren L, Bäckström D, Lawson RA, Macleod AD, Counsell CE, Paquet C, DeLena C, D'Antonio F, Pilotto A, Padovani A, Blanc F, Falup-Pecurariu C, Lewis SJG, Rejdak K, Papuc E, Hort J, Nedelska Z, O'Brien J, Bonanni L, Marquié M, Boada M, Pytel V, Abdelnour C, Alcolea D, Beyer K, Tysnes OB, Aarsland D, Maple-Grødem J.
    ​Cognitive and Motor Decline in Dementia with Lewy Bodies and Parkinson's Disease Dementia Dementia Mov Disord Clin Pract. 
    
    
27. Guu TW, Muurling M, Khan Z, Kalafatis C, Aarsland D, Ffytche D, Brem AK.
    Wearable devices: underrepresentation in the ageing society Lancet Digit Health. 
    
    
28. Hella MNP, Bergland AK, Soennesyn H, Halaas NB, Watne LO, Bonanni L, Aarsland D
    ​What we know about the possible link between delirium and dementia with Lewy bodies, and why we need to learn more Acta Psychiatr Scand. 
    
    

29. Huber H, Ashton NJ, Schieren A, Montoliu-Gaya L, Molfetta GD, Brum WS, Lantero-Rodriguez J, Grötschel L, Stoffel-Wagner B, Coenen M, Weinhold L, Schmid M, Blennow K, Stehle P, Zetterberg H, Simon MC.​
    Levels of Alzheimer's disease blood biomarkers are altered after food intake-A pilot intervention study in healthy adults​
    

30. Inguanzo A, Poulakis K, Mohanty R, Schwarz CG, Przybelski SA, Diaz-Galvan P, Lowe VJ, Boeve BF, Lemstra AW, van de Beek M, van der Flier W, Barkhof F, Blanc F, Loureiro de Sousa P, Philippi N, Cretin B, Demuynck C, Nedelska Z, Hort J, Segura B, Junque C, Oppedal K, Aarsland D, Westman E, Kantarci K, Ferreira D. 
    MRI data-driven clustering reveals different subtypes of Dementia with Lewy bodies. NPJ Parkinsons Dis. 
    
    
31. Janelidze S, Bali D, Ashton NJ, Barthélemy NR, Vanbrabant J, Stoops E, Vanmechelen E, He Y, Dolado AO, Triana-Baltzer G, Pontecorvo MJ, Zetterberg H, Kolb H, Vandijck M, Blennow K, Bateman RJ, Hansson O.
    ​Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease Brain.
    
    
32. Jaramillo-Jimenez A, Giil LM, Borda MG, Tovar-Rios DA, Kristiansen KA, Bruheim P, Aarsland D, Barreto GE, Berge RK.
    Serum TCA cycle metabolites in Lewy bodies dementia and Alzheimer's disease: Network analysis and cognitive prognosis Mitochondrion.
    
    
33. Jaramillo-Jimenez A, Tovar-Rios DA, Ospina JA, Mantilla-Ramos YJ, Loaiza-López D, Henao Isaza V, Zapata Saldarriaga LM, Cadavid Castro V, Suarez-Revelo JX, Bocanegra Y, Lopera F, Pineda-Salazar DA, Tobón Quintero CA, Ochoa-Gomez JF, Borda MG, Aarsland D, Bonanni L, Brønnick K.
    ​Spectral features of resting-state EEG in Parkinson's Disease: A multicenter study using functional data analysis Clin Neurophysiol.
    
    
34. Lantero-Rodriguez J, Vrillon A, Fernández-Lebrero A, Ortiz-Romero P, Snellman A, Montoliu-Gaya L, Brum WS, Cognat E, Dumurgier J, Puig-Pijoan A, Navalpotro-Gómez I, García-Escobar G, Karikari TK, Vanmechelen E, Ashton NJ, Zetterberg H, Suárez-Calvet M, Paquet C, Blennow K.
    Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts Alzheimers Res Ther. 
    
    
35. Lennol MP, Ashton NJ, Moreno-Pérez O, García-Ayllón MS, Ramos-Rincon JM, Andrés M, León-Ramírez JM, Boix V, Gil J, Blennow K, Merino E, Zetterberg H, Sáez-Valero J. 
    
    Transient Changes in the Plasma of Astrocytic and Neuronal Injury Biomarkers in COVID-19 Patients without Neurological Syndromes. Int J Mol Sci. ​
    
    
36. Lennon MJ, Brooker H, Creese B, Thayanandan T, Rigney G, Aarsland D, Hampshire A, Ballard C, Corbett A, Raymont V. 
    

    Lifetime Traumatic Brain Injury and Cognitive Domain Deficits in Late Life: The PROTECT-TBI Cohort Study. J Neurotrauma. 
    
    

37. Levin H, Lybeck A, Frigyesi A, Arctaedius I, Thorgeirsdóttir B, Annborn M, Moseby-Knappe M, Nielsen N, Cronberg T, Ashton NJ, Zetterberg H, Blennow K, Friberg H, Mattsson-Carlgren N. 
    Plasma neurofilament light is a predictor of neurological outcome 12 h aftercardiac arrest. Crit Care.
    

38. Lorentzen IM, Espenes J, Hessen E, Waterloo K, Bråthen G, Timón S, Aarsland D, Fladby T, Kirsebom BE. ​​
    Regression-based norms for the FAS phonemic fluency test for ages 40-84 basedon a Norwegian sample. Appl Neuropsychol Adult. ​​
    

39. Mattsson-Carlgren N, Salvadó G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H, Ossenkoppele R, Betthauser TJ, Cody KA, Jonaitis EM, Langhough R, Palmqvist S, Blennow K, Janelidze S, Johnson SC, Hansson O. 
    Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer DiseaseUsing Plasma Biomarkers. JAMA Neurol.​​
    

40. Mgaieth F, Baksh RA, Startin CM, Hamburg S, Hithersay R, Pape S, Zetterberg H, Ashton NJ, Tamayo-Elizalde M, Saini F, Idris M, Consortium TL, Strydom A.
    Exploring semantic verbal fluency patterns and their relationship to age and Alzheimer's disease in adults with Down syndrome Alzheimers Dement. 

41. Montoliu-Gaya L, Benedet AL, Tissot C, Vrillon A, Ashton NJ, Brum WS, Lantero-Rodriguez J, Stevenson J, Nilsson J, Sauer M, Rahmouni N, Brinkmalm G, Lussier FZ, Pascoal TA, Skoog I, Kern S, Zetterberg H, Paquet C, Gobom J, Rosa-Neto P, Blennow K.
    ​Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies Nat Aging. 
    

42. Muurling M, Pasmooij AMG, Koychev I, Roik D, Froelich L, Schwertner E, Religa D, Abdelnour C, Boada M, Almici M, Galluzzi S, Cardoso S, de Mendonça A, Owens AP, Kuruppu S, Gjestsen MT, Lazarou I, Gkioka M, Tsolaki M, Diaz A, Gove D, Visser PJ, Aarsland D, Lucivero F, de Boer C; RADAR-AD Consortium.
    Ethical challenges of using remote monitoring technologies for clinical research: A case study of the role of local research ethics committees in the RADAR-AD study PLoS One. ​
    

43. O'Connor A, Abel E, Benedet AL, Poole T, Ashton N, Weston PSJ, Heslegrave AJ, Ryan N, Barker S, Polke JM, Blennow K, Zetterberg H, Fox NC. 
    Plasma GFAP in presymptomatic and symptomatic familial Alzheimer's disease: alongitudinal cohort study.​ J Neurol Neurosurg Psychiatry. ​​​​​

44. Pedersen CC, Ushakova A, Skogseth RE, Alves G, Tysnes OB, Aarsland D, Lange J, Maple-Grødem J.
    Inflammatory Biomarkers in Newly Diagnosed Patients With Parkinson Disease and Related Neurodegenerative Disorders Neurol Neuroimmunol Neuroinflamm. 

45. Pisani S, Gunasekera B, Lu Y, Vignando M, Ffytche D, Aarsland D, Chaudhuri KR, Ballard C, Lee JY, Kim YK, Velayudhan L, Bhattacharyya S. 
    Grey matter volume loss in Parkinson's disease psychosis and its relationship with serotonergic gene expression: A meta-analysis. Neurosci Biobehav Rev.

46. Römer B, Dalen I, Ballard C, Aarsland D.
    The course of depressive symptoms in Lewy body dementia and Alzheimer's disease J Affect Disord. 

47. Sandvig HV, Aam S, Alme KN, Askim T, Beyer MK, Ellekjær H, Ihle-Hansen H, Lydersen S, Mollnes TE, Munthe-Kaas R, Næss H, Saltvedt I, Seljeseth YM, Thingstad P, Wethal T, Knapskog AB. 
    Plasma Inflammatory Biomarkers Are Associated With Poststroke Cognitive Impairment: The Nor-COAST Study. Stroke. 

48. Snellman A, Ekblad LL, Tuisku J, Koivumäki M, Ashton NJ, Lantero-Rodriguez J, Karikari TK, Helin S, Bucci M, Löyttyniemi E, Parkkola R, Karrasch M, Schöll M, Zetterberg H, Blennow K, Rinne JO. 
    
    APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly. Alzheimers Res Ther. ​
    
    
49. Snellman A, Ekblad LL, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Pietilä E, Koivumäki M, Helin S, Karrasch M, Zetterberg H, Blennow K, Rinne JO.
    Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease Neurobiol Dis. 
    
    

50. Sunde AL, Alsnes  IV, Aarsland D, Ashton NJ, Tovar-Rios DA, De Santis G, Blennow K, Zettererg H, Kjosavik SR.
    Preanalytical stability of plasma biomarkers for Alzheimer's disease pathology. Alzheimers Dement (Amst). 

51. Van Egroo M, Riphagen JM, Ashton NJ, Janelidze S, Sperling RA, Johnson KA, Yang HS, Bennett DA, Blennow K, Hansson O, Zetterberg H, Jacobs HIL.
    Ultra-high field imaging, plasma markers and autopsy data uncover a specific rostral locus coeruleus vulnerability to hyperphosphorylated tau. Mol Psychiatry. 

52. Vossius C, Borda MG, Lichtwarck B, Myhre J, Sollid MIV, Borza T, Feiring IH, Benth JŠ, Bergh S. 
    Body mass index in nursing home residents during the first year after admission. BMC Nutr. 

53. Yakoub Y, Ashton NJ, Strikwerda-Brown C, Montoliu-Gaya L, Karikari TK, Kac PR, Gonzalez-Ortiz F, Gallego-Rudolf J, Meyer PF, St-Onge F, Schöll M, Soucy JP, Breitner JCS, Zetterberg H, Blennow K, Poirier J, Villeneuve S; PREVENT-AD Research Group.​
    Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease Alzheimers Dement. 
    ​
    

​​